1
|
Lu J, Huang L, Liang H, Wang Z, Kato T, Liu Y, Maruoka K. Asymmetric Phase-Transfer Alkylation of Readily Available Aryl Aldehyde Schiff Bases of Amino Acid Ethyl Esters. Org Lett 2024; 26:4163-4167. [PMID: 38289671 DOI: 10.1021/acs.orglett.3c04290] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/25/2024]
Abstract
Asymmetric phase-transfer alkylation of the N-(arylmethylene)-α-alkylamino acid ethyl esters and N-(arylmethylene)glycine ethyl esters was found to be catalyzed by the (R)- or (S)-Simplified Maruoka Catalyst with high efficiency and excellent enantioselectivity. This approach was successfully applied to the enantioselective formal synthesis of the angiotensin II type 2 receptor (AT2R) antagonists Olodanrigan and LX9211, and the practical aspect is demonstrated by the kilogram-scale synthesis of a key intermediate for the synthesis of LX9211.
Collapse
Affiliation(s)
- Jinying Lu
- School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, China
- Guangdong Provincial Key Laboratory of Plant Resources Biorefinery, Guangdong University of Technology, Guangzhou 510006, China
| | - Lei Huang
- School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, China
- Guangdong Provincial Key Laboratory of Plant Resources Biorefinery, Guangdong University of Technology, Guangzhou 510006, China
| | - Huatai Liang
- School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, China
- Guangdong Provincial Key Laboratory of Plant Resources Biorefinery, Guangdong University of Technology, Guangzhou 510006, China
| | - Zhe Wang
- School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, China
- Guangdong Provincial Key Laboratory of Plant Resources Biorefinery, Guangdong University of Technology, Guangzhou 510006, China
| | - Terumasa Kato
- School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, China
- Guangdong Provincial Key Laboratory of Plant Resources Biorefinery, Guangdong University of Technology, Guangzhou 510006, China
- Laboratory of Organocatalytic Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo, Kyoto 606-8501, Japan
| | - Yan Liu
- School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, China
- Guangdong Provincial Key Laboratory of Plant Resources Biorefinery, Guangdong University of Technology, Guangzhou 510006, China
| | - Keiji Maruoka
- School of Chemical Engineering and Light Industry, Guangdong University of Technology, Guangzhou 510006, China
- Guangdong Provincial Key Laboratory of Plant Resources Biorefinery, Guangdong University of Technology, Guangzhou 510006, China
- Laboratory of Organocatalytic Chemistry, Graduate School of Pharmaceutical Sciences, Kyoto University, Sakyo, Kyoto 606-8501, Japan
| |
Collapse
|
2
|
Guo Y, Huang X, Liao W, Meng L, Xu D, Ye C, Chen L, Hu T. Discovery and Optimization of Highly Potent and Selective AT 2R Antagonists to Relieve Peripheral Neuropathic Pain. ACS OMEGA 2021; 6:15412-15420. [PMID: 34151119 PMCID: PMC8210434 DOI: 10.1021/acsomega.1c01866] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/08/2021] [Accepted: 05/10/2021] [Indexed: 05/08/2023]
Abstract
The angiotensin II type 2 receptor (AT2R) has attracted much attention as a potential target for the relief of neuropathic pain, which represents an area of unmet clinical need. A series of 1,2,3,4-tetrahydroisoquinolines with a benzoxazole side-chain were discovered as potent AT2R antagonists. Rational optimization resulted in compound 15, which demonstrated both excellent antagonistic activity against AT2R in vitro and analgesic efficacy in a rat chronic constriction injury model. Its favorable physicochemical properties and oral bioavailability make it a promising therapeutic candidate for neuropathic pain.
Collapse
Affiliation(s)
- Yanghui Guo
- Shanghai
Institute of Drug Discovery, Zhejiang Hisun
Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China
| | - Xiangui Huang
- Shanghai
Institute of Drug Discovery, Zhejiang Hisun
Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China
| | - Weiwei Liao
- Shanghai
Institute of Drug Discovery, Zhejiang Hisun
Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China
| | - Lichen Meng
- Shanghai
Institute of Drug Discovery, Zhejiang Hisun
Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China
| | - Daiwang Xu
- Shanghai
Institute of Drug Discovery, Zhejiang Hisun
Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China
| | - Cheng Ye
- Shanghai
Institute of Drug Discovery, Zhejiang Hisun
Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China
| | - Lei Chen
- Shanghai
Institute of Drug Discovery, Zhejiang Hisun
Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China
- Zhejiang
Hisun Pharmaceutical Co., Ltd., 46 Waisha Road, Taizhou, Zhejiang 318000, China
| | - Taishan Hu
- Shanghai
Institute of Drug Discovery, Zhejiang Hisun
Pharmaceutical Co., Ltd., Building 25, 301 Minqiang Road, Shanghai 201612, China
| |
Collapse
|
3
|
Wannberg J, Gising J, Lindman J, Salander J, Gutiérrez-de-Terán H, Ablahad H, Hamid S, Grönbladh A, Spizzo I, Gaspari TA, Widdop RE, Hallberg A, Backlund M, Leśniak A, Hallberg M, Larhed M. N-(Methyloxycarbonyl)thiophene sulfonamides as high affinity AT2 receptor ligands. Bioorg Med Chem 2020; 29:115859. [PMID: 33309749 DOI: 10.1016/j.bmc.2020.115859] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/16/2020] [Revised: 10/29/2020] [Accepted: 10/31/2020] [Indexed: 12/14/2022]
Abstract
A series of meta-substituted acetophenone derivatives, encompassing N-(alkyloxycarbonyl)thiophene sulfonamide fragments have been synthesized. Several selective AT2 receptor ligands were identified, among those a tert-butylimidazole derivative (20) with a Ki of 9.3 nM, that demonstrates a high stability in human liver microsomes (t½ = 62 min) and in human hepatocytes (t½ = 194 min). This methyloxycarbonylthiophene sulfonamide is a 20-fold more potent binder to the AT2 receptor and is considerably more stable in human liver microsomes, than a previously reported and broadly studied structurally related AT2R prototype antagonist 3 (C38). Ligand 20 acts as an AT2R agonist and caused an AT2R mediated concentration-dependent vasorelaxation of pre-contracted mouse aorta. Furthermore, in contrast to imidazole derivative C38, the tert-butylimidazole derivative 20 is a poor inhibitor of CYP3A4, CYP2D6 and CYP2C9. It is demonstrated herein that smaller alkyloxycarbonyl groups make the ligands in this series of AT2R selective compounds less prone to degradation and that a high AT2 receptor affinity can be retained after truncation of the alkyloxycarbonyl group. Binding modes of the most potent AT2R ligands were explored by docking calculations combined with molecular dynamics simulations.
Collapse
Affiliation(s)
- Johan Wannberg
- Department of Medicinal Chemistry, Science for Life Laboratory, BMC, Uppsala University, Box 574, SE-751 23 Uppsala, Sweden
| | - Johan Gising
- The Beijer Laboratory, Department of Medicinal Chemistry, Uppsala University, BMC, Box 591, 751 24 Uppsala, Sweden
| | - Jens Lindman
- The Beijer Laboratory, Department of Medicinal Chemistry, Uppsala University, BMC, Box 591, 751 24 Uppsala, Sweden
| | - Jessica Salander
- Department of Cell and Molecular Biology, BMC, Box 596, Uppsala University, SE-751 24 Uppsala, Sweden
| | - Hugo Gutiérrez-de-Terán
- Department of Cell and Molecular Biology, BMC, Box 596, Uppsala University, SE-751 24 Uppsala, Sweden
| | - Hanin Ablahad
- The Beijer Laboratory, Department of Pharmaceutical Biosciences, Uppsala University, BMC, Box 591, 751 24 Uppsala, Sweden; Department of Pharmacology and Biomedicine Discovery Institute, Monash University, Clayton 3800, VIC, Australia
| | - Selin Hamid
- The Beijer Laboratory, Department of Pharmaceutical Biosciences, Uppsala University, BMC, Box 591, 751 24 Uppsala, Sweden; Department of Pharmacology and Biomedicine Discovery Institute, Monash University, Clayton 3800, VIC, Australia
| | - Alfhild Grönbladh
- The Beijer Laboratory, Department of Pharmaceutical Biosciences, Uppsala University, BMC, Box 591, 751 24 Uppsala, Sweden
| | - Iresha Spizzo
- Department of Pharmacology and Biomedicine Discovery Institute, Monash University, Clayton 3800, VIC, Australia
| | - Tracey A Gaspari
- Department of Pharmacology and Biomedicine Discovery Institute, Monash University, Clayton 3800, VIC, Australia
| | - Robert E Widdop
- Department of Pharmacology and Biomedicine Discovery Institute, Monash University, Clayton 3800, VIC, Australia
| | - Anders Hallberg
- Department of Medicinal Chemistry, Uppsala University, BMC, Box 574, 751 23 Uppsala, Sweden
| | - Maria Backlund
- Department of Pharmacy, Uppsala University, Uppsala, Sweden; Uppsala University Drug Optimization and Pharmaceutical Profiling Platform (UDOPP), Science for Life Laboratory, Uppsala, Sweden
| | - Anna Leśniak
- Department of Pharmacodynamics, Centre for Preclinical Research and Technology, Medical University of Warsaw, Banacha 1B Str., 02-097 Warsaw, Poland
| | - Mathias Hallberg
- The Beijer Laboratory, Department of Pharmaceutical Biosciences, Uppsala University, BMC, Box 591, 751 24 Uppsala, Sweden
| | - Mats Larhed
- Department of Medicinal Chemistry, Science for Life Laboratory, BMC, Uppsala University, Box 574, SE-751 23 Uppsala, Sweden; The Beijer Laboratory, Department of Medicinal Chemistry, Uppsala University, BMC, Box 591, 751 24 Uppsala, Sweden.
| |
Collapse
|
4
|
Hardegger LA, Mallet F, Bianchi B, Cai C, Grand-Guillaume Perrenoud A, Humair R, Kaehny R, Lanz S, Li C, Li J, Rampf F, Shi L, Spoendlin C, Stäuble J, Teng S, Tian X, Wietfeld B, Yang Y, Yu B, Zepperitz C, Zhang X, Zhang Y. Toward a Scalable Synthesis and Process for EMA401, Part I: Late Stage Process Development, Route Scouting, and ICH M7 Assessment. Org Process Res Dev 2020. [DOI: 10.1021/acs.oprd.0c00215] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Leo A. Hardegger
- Chemical and Analytical Development, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Franck Mallet
- Pharmaceutical and Analytical Development, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Barbara Bianchi
- Chemical and Analytical Development, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Chunlong Cai
- Suzhou Novartis Technical Development Co., Ltd., Changshu City 215537, China
| | | | - Roger Humair
- Chemical and Analytical Development, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Richard Kaehny
- Chemical and Analytical Development, Novartis Pharma AG, 4002 Basel, Switzerland
| | | | - Cheng Li
- Suzhou Novartis Technical Development Co., Ltd., Changshu City 215537, China
| | - Jialiang Li
- Suzhou Novartis Technical Development Co., Ltd., Changshu City 215537, China
| | - Florian Rampf
- Chemical and Analytical Development, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Lei Shi
- Suzhou Novartis Technical Development Co., Ltd., Changshu City 215537, China
| | - Christoph Spoendlin
- Chemical and Analytical Development, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Jeannine Stäuble
- Pharmaceutical and Analytical Development, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Shangjun Teng
- Suzhou Novartis Technical Development Co., Ltd., Changshu City 215537, China
| | - Xiangguang Tian
- Suzhou Novartis Technical Development Co., Ltd., Changshu City 215537, China
| | - Bernhard Wietfeld
- Chemical and Analytical Development, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Yao Yang
- Suzhou Novartis Technical Development Co., Ltd., Changshu City 215537, China
| | - Bo Yu
- Suzhou Novartis Technical Development Co., Ltd., Changshu City 215537, China
| | - Christine Zepperitz
- Chemical and Analytical Development, Novartis Pharma AG, 4002 Basel, Switzerland
| | - Xuesong Zhang
- Suzhou Novartis Technical Development Co., Ltd., Changshu City 215537, China
| | - Yong Zhang
- Suzhou Novartis Technical Development Co., Ltd., Changshu City 215537, China
| |
Collapse
|
5
|
Liu J, Han J, Izawa K, Sato T, White S, Meanwell NA, Soloshonok VA. Cyclic tailor-made amino acids in the design of modern pharmaceuticals. Eur J Med Chem 2020; 208:112736. [PMID: 32966895 DOI: 10.1016/j.ejmech.2020.112736] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2020] [Revised: 08/03/2020] [Accepted: 08/04/2020] [Indexed: 12/15/2022]
Abstract
Tailor-made AAs are indispensable components of modern medicinal chemistry and are becoming increasingly prominent in new drugs. In fact, about 30% of small-molecule pharmaceuticals contain residues of tailor-made AAs or structurally related diamines and amino-alcohols. Cyclic tailor-made AAs present a particular value to rational structural design by virtue of their local conformational constraints and are widely used in lead optimization programs. The present review article highlights 34 compounds, all of which are derived from cyclic AAs, representing recently-approved, small-molecule pharmaceuticals as well as promising drug candidates currently in various phases of clinical study. For each compound, the discussion includes the discovery, therapeutic profile and optimized synthesis, with a focus on the preparation of cyclic tailor-made AA as the principal structural feature. The present review article is intended to serve as a reference source for organic, medicinal and process chemists along with other professionals working in the fields of drug design and pharmaceutical discovery.
Collapse
Affiliation(s)
- Jiang Liu
- Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, 210037, Jiangsu, China
| | - Jianlin Han
- Jiangsu Co-Innovation Center of Efficient Processing and Utilization of Forest Resources, College of Chemical Engineering, Nanjing Forestry University, Nanjing, 210037, Jiangsu, China
| | - Kunisuke Izawa
- Hamari Chemicals Ltd., 1-4-29 Kunijima, Higashi-Yodogawa-ku, Osaka, 533-0024, Japan.
| | - Tatsunori Sato
- Hamari Chemicals Ltd., 1-4-29 Kunijima, Higashi-Yodogawa-ku, Osaka, 533-0024, Japan
| | - Sarah White
- Oakwood Chemical, Inc, 730 Columbia Hwy. N, Estill, SC, 29918, USA
| | - Nicholas A Meanwell
- Department of Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, PO Box, 4000, Princeton, NJ, 08543 4000, United States
| | - Vadim A Soloshonok
- Department of Organic Chemistry I, Faculty of Chemistry, University of the Basque Country UPV/EHU, Paseo Manuel Lardizábal 3, 20018, San Sebastián, Spain; IKERBASQUE, Basque Foundation for Science, María Díaz de Haro 3, Plaza Bizkaia, 48013, Bilbao, Spain.
| |
Collapse
|
6
|
Yang EL, Sun B, Huang ZY, Lin JG, Jiao B, Xiang L. Synthesis, Purification, and Selective β 2-AR Agonist and Bronchodilatory Effects of Catecholic Tetrahydroisoquinolines from Portulaca oleracea. JOURNAL OF NATURAL PRODUCTS 2019; 82:2986-2993. [PMID: 31625751 DOI: 10.1021/acs.jnatprod.9b00418] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/10/2023]
Abstract
A green, biomimetic, phosphate-mediated Pictet-Spengler reaction was used in the synthesis of three catecholic tetrahydroisoquinolines, 1, 2, and 12, present in the medicinal plant Portulaca oleracea, as well as their analogues 3-11, 13, and 14, with dopamine hydrochloride and aldehydes as the substrates. AB-8 macroporous resin column chromatography was applied for purification of the products from the one-step high-efficacy synthesis. It eliminated the difficulties in the isolation of catecholic tetrahydroisoquinolines from the aqueous reaction system and unreacted dopamine hydrochloride. Activity screening in CHO-K1/Gα15 cell models consistently expressing α1B-, β1-, or β2-adrenergic receptors indicated that 12 and 2, compounds that are present in P. oleracea, possessed the most potent β2-adrenergic receptor agonist activity and 2 was a selective β2-adrenergic receptor agonist at the concentration of 100 μM. Both 12 and 2 exhibited dose-dependent bronchodilator effects on the histamine-induced contraction of isolated guinea-pig tracheal smooth muscle, with EC50 values of 0.8 and 2.8 μM, respectively. These findings explain the scientific rationale of P. oleracea use as an antiasthmatic herb in folk medicine and provide the basis for the discovery of novel antiasthma drugs.
Collapse
Affiliation(s)
- Er-Lan Yang
- Key Laboratory of Chemical Biology (Ministry of Education), Institute of Pharmacognosy, School of Pharmaceutical Sciences , Shandong University , Jinan , Shandong 250012 , People's Republic of China
| | - Bin Sun
- National Glycoengineering Research Center , Shandong University , Jinan , Shandong 250012 , People's Republic of China
| | - Zi-Yi Huang
- Key Laboratory of Chemical Biology (Ministry of Education), Institute of Pharmacognosy, School of Pharmaceutical Sciences , Shandong University , Jinan , Shandong 250012 , People's Republic of China
| | - Jian-Guang Lin
- Key Laboratory of Chemical Biology (Ministry of Education), Institute of Pharmacognosy, School of Pharmaceutical Sciences , Shandong University , Jinan , Shandong 250012 , People's Republic of China
| | - Bo Jiao
- Key Laboratory of Chemical Biology (Ministry of Education), Institute of Pharmacognosy, School of Pharmaceutical Sciences , Shandong University , Jinan , Shandong 250012 , People's Republic of China
| | - Lan Xiang
- Key Laboratory of Chemical Biology (Ministry of Education), Institute of Pharmacognosy, School of Pharmaceutical Sciences , Shandong University , Jinan , Shandong 250012 , People's Republic of China
| |
Collapse
|
7
|
Institutional profile: the national Swedish academic drug discovery & development platform at SciLifeLab. Future Sci OA 2017; 3:FSO176. [PMID: 28670468 PMCID: PMC5481862 DOI: 10.4155/fsoa-2017-0013] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2017] [Accepted: 01/23/2017] [Indexed: 11/29/2022] Open
Abstract
The Science for Life Laboratory Drug Discovery and Development Platform (SciLifeLab DDD) was established in Stockholm and Uppsala, Sweden, in 2014. It is one of ten platforms of the Swedish national SciLifeLab which support projects run by Swedish academic researchers with large-scale technologies for molecular biosciences with a focus on health and environment. SciLifeLab was created by the coordinated effort of four universities in Stockholm and Uppsala: Stockholm University, Karolinska Institutet, KTH Royal Institute of Technology and Uppsala University, and has recently expanded to other Swedish university locations. The primary goal of the SciLifeLab DDD is to support selected academic discovery and development research projects with tools and resources to discover novel lead therapeutics, either molecules or human antibodies. Intellectual property developed with the help of SciLifeLab DDD is wholly owned by the academic research group. The bulk of SciLifeLab DDD's research and service activities are funded from the Swedish state, with only consumables paid by the academic research group through individual grants.
Collapse
|